NCT06615388

Brief Summary

Low energy availability (LEA) signifies a condition where the body lacks sufficient energy to support essential physiological functions crucial for maintaining optimal health (1). This energy insufficiency can be exacerbated by the demands of sports and exercise, resulting in negative impacts on various physiological, psychological, and sports performance (11, 8, 2). While LEA is commonly associated with cardiovascular abnormalities, such as early atherosclerosis, endothelial dysfunction, and lower blood pressure, the existing body of research faces limitations, including small sample sizes and primarily exploratory approaches (2). Additionally, despite a growing body of evidence suggesting a strong link between DNA methylation (an epigenetic modification influencing gene expression by tagging specific parts of the DNA code) and cardiovascular disease (9, 6), there has been no prior investigation exploring the interplay between DNA methylation, cardiovascular disease, and LEA. To better understand LEA and its effects on cardiovascular health, it is imperative to address these limitations through further research. Utilising more comprehensive markers of cardiovascular disease and expanding the scope of investigations will contribute to a great understanding of LEA and its implications on cardiovascular health (10).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
126

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2024

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

September 19, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 26, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 13, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 13, 2026

Completed
Last Updated

September 26, 2024

Status Verified

September 1, 2024

Enrollment Period

1.3 years

First QC Date

September 19, 2024

Last Update Submit

September 24, 2024

Conditions

Keywords

low energy availabilityCardiovascular DiseasesPhysically active females

Outcome Measures

Primary Outcomes (1)

  • The primary outcome is to measure the cardiovascular risk factors associated with LEA in trained to elite female athletes.

    1 year

Secondary Outcomes (1)

  • The secondary outcome is to measure the DNA methylation characteristics of trained to elite-level female athletes?

    1 year

Study Arms (1)

Physically active females

Physically active females with and with low energy availability

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The team plans to include 126 trained to elite female athletes from local sports clubs near the Liverpool area to participate in the study.

You may qualify if:

  • Cisgender females
  • Aged 18 to 35 to avoid recruiting peri or postmenopausal females
  • Trained to elite female athletes based on McKay and colleagues\' (2021) criteria for participation classification framework. For example, trained (local-level representation), highly trained (competing at the national level) and elite (competing at the international level).
  • Females living in the United Kingdom.

You may not qualify if:

  • Biological Males
  • Females aged over 35
  • Sedentary females
  • Habitual smokers
  • Volunteers with any previous experience with Syncope
  • Volunteers with any previous diagnosis of ischaemic heart disease, myopathy or any neuromuscular disorder
  • Anticoagulants users
  • Pregnant women
  • Volunteers on lipid-lowering medication
  • Taking hormonal contraception (copper IUDs are acceptable)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Liverpool Hope University

Liverpool, Merseyside, L16 9JD, United Kingdom

RECRUITING

Related Publications (11)

  • Wasserfurth P, Palmowski J, Hahn A, Kruger K. Reasons for and Consequences of Low Energy Availability in Female and Male Athletes: Social Environment, Adaptations, and Prevention. Sports Med Open. 2020 Sep 10;6(1):44. doi: 10.1186/s40798-020-00275-6.

    PMID: 32910256BACKGROUND
  • Mountjoy M, Sundgot-Borgen J, Burke L, Ackerman KE, Blauwet C, Constantini N, Lebrun C, Lundy B, Melin A, Meyer N, Sherman R, Tenforde AS, Torstveit MK, Budgett R. International Olympic Committee (IOC) Consensus Statement on Relative Energy Deficiency in Sport (RED-S): 2018 Update. Int J Sport Nutr Exerc Metab. 2018 Jul 1;28(4):316-331. doi: 10.1123/ijsnem.2018-0136. Epub 2018 May 17. No abstract available.

    PMID: 29771168BACKGROUND
  • Melin AK, Heikura IA, Tenforde A, Mountjoy M. Energy Availability in Athletics: Health, Performance, and Physique. Int J Sport Nutr Exerc Metab. 2019 Mar 1;29(2):152-164. doi: 10.1123/ijsnem.2018-0201. Epub 2019 Feb 26.

    PMID: 30632422BACKGROUND
  • McKay AKA, Stellingwerff T, Smith ES, Martin DT, Mujika I, Goosey-Tolfrey VL, Sheppard J, Burke LM. Defining Training and Performance Caliber: A Participant Classification Framework. Int J Sports Physiol Perform. 2022 Feb 1;17(2):317-331. doi: 10.1123/ijspp.2021-0451. Epub 2022 Dec 29.

    PMID: 34965513BACKGROUND
  • Loucks AB, Verdun M, Heath EM. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol (1985). 1998 Jan;84(1):37-46. doi: 10.1152/jappl.1998.84.1.37.

    PMID: 9451615BACKGROUND
  • Kazmi N, Elliott HR, Burrows K, Tillin T, Hughes AD, Chaturvedi N, Gaunt TR, Relton CL. Associations between high blood pressure and DNA methylation. PLoS One. 2020 Jan 30;15(1):e0227728. doi: 10.1371/journal.pone.0227728. eCollection 2020.

    PMID: 31999706BACKGROUND
  • Elliott-Sale KJ, Minahan CL, de Jonge XAKJ, Ackerman KE, Sipila S, Constantini NW, Lebrun CM, Hackney AC. Methodological Considerations for Studies in Sport and Exercise Science with Women as Participants: A Working Guide for Standards of Practice for Research on Women. Sports Med. 2021 May;51(5):843-861. doi: 10.1007/s40279-021-01435-8. Epub 2021 Mar 16.

    PMID: 33725341BACKGROUND
  • De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G; Expert Panel. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad: 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013. Br J Sports Med. 2014 Feb;48(4):289. doi: 10.1136/bjsports-2013-093218.

    PMID: 24463911BACKGROUND
  • Chilunga FP, Henneman P, Venema A, Meeks KA, Gonzalez JR, Ruiz-Arenas C, Requena-Mendez A, Beune E, Spranger J, Smeeth L, Bahendeka S, Owusu-Dabo E, Klipstein-Grobusch K, Adeyemo A, Mannens MM, Agyemang C. DNA methylation as the link between migration and the major noncommunicable diseases: the RODAM study. Epigenomics. 2021 May;13(9):653-666. doi: 10.2217/epi-2020-0329. Epub 2021 Apr 23.

    PMID: 33890479BACKGROUND
  • Black K, Slater J, Brown RC, Cooke R. Low Energy Availability, Plasma Lipids, and Hormonal Profiles of Recreational Athletes. J Strength Cond Res. 2018 Oct;32(10):2816-2824. doi: 10.1519/JSC.0000000000002540.

    PMID: 29624522BACKGROUND
  • Areta JL, Taylor HL, Koehler K. Low energy availability: history, definition and evidence of its endocrine, metabolic and physiological effects in prospective studies in females and males. Eur J Appl Physiol. 2021 Jan;121(1):1-21. doi: 10.1007/s00421-020-04516-0. Epub 2020 Oct 23.

    PMID: 33095376BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Genetic material (DNA) in cells collected from a buccal cheek smear swab test. Methylation analysis (study of cell function) on the buccal cells will be performed.

MeSH Terms

Conditions

Cardiovascular Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2024

First Posted

September 26, 2024

Study Start

September 10, 2024

Primary Completion

December 13, 2025

Study Completion

February 13, 2026

Last Updated

September 26, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

All participant data will be kept confidential in line with GDPR.

Locations